Poster: AML-295 AGILE: A Global, Randomized, Double-Blind, Phase 3 Study of Ivosidenib + Azacitidine Versus Placebo + Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia With an IDH1 Mutation

Clinical Lymphoma Myeloma and Leukemia(2022)

引用 0|浏览14
暂无评分
关键词
acute myeloid leukemia,idh1 mutation,ivosidenib,double-blind
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要